400 related articles for article (PubMed ID: 34712615)
1. NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma.
Garofalo C; De Marco C; Cristiani CM
Front Oncol; 2021; 11():754541. PubMed ID: 34712615
[TBL] [Abstract][Full Text] [Related]
2. Helper Innate Lymphoid Cells-Unappreciated Players in Melanoma Therapy.
Garofalo C; Cerantonio A; Muscoli C; Mollace V; Viglietto G; De Marco C; Cristiani CM
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765891
[TBL] [Abstract][Full Text] [Related]
3. Defective Natural Killer Cells in Melanoma: Role of NKG2D in Pathogenesis and Immunotherapy.
Touboul R; Zaravinos A; Bonavida B
Crit Rev Immunol; 2021; 41(2):45-76. PubMed ID: 34348002
[TBL] [Abstract][Full Text] [Related]
4. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
5. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
6. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
7. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
8. Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?
Lanuza PM; Pesini C; Arias MA; Calvo C; Ramirez-Labrada A; Pardo J
Front Immunol; 2019; 10():3010. PubMed ID: 31998304
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects.
Bassani B; Baci D; Gallazzi M; Poggi A; Bruno A; Mortara L
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30939820
[No Abstract] [Full Text] [Related]
10. Modulation of innate immunity in the tumor microenvironment.
Gonzalez-Gugel E; Saxena M; Bhardwaj N
Cancer Immunol Immunother; 2016 Oct; 65(10):1261-8. PubMed ID: 27344341
[TBL] [Abstract][Full Text] [Related]
11. Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.
Pachynski RK; Wang P; Salazar N; Zheng Y; Nease L; Rosalez J; Leong WI; Virdi G; Rennier K; Shin WJ; Nguyen V; Butcher EC; Zabel BA
Front Immunol; 2019; 10():983. PubMed ID: 31139180
[TBL] [Abstract][Full Text] [Related]
12. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
[TBL] [Abstract][Full Text] [Related]
13. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
14. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.
Kim KS; Kim DH; Kim DH
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33918941
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.
Marzagalli M; Ebelt ND; Manuel ER
Semin Cancer Biol; 2019 Dec; 59():236-250. PubMed ID: 31404607
[TBL] [Abstract][Full Text] [Related]
17. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
18. Arrested development: suppression of NK cell function in the tumor microenvironment.
Riggan L; Shah S; O'Sullivan TE
Clin Transl Immunology; 2021; 10(1):e1238. PubMed ID: 33456775
[TBL] [Abstract][Full Text] [Related]
19. Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy.
Rethacker L; Roelens M; Bejar C; Maubec E; Moins-Teisserenc H; Caignard A
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810032
[TBL] [Abstract][Full Text] [Related]
20. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
MandalĂ M; Massi D
Handb Exp Pharmacol; 2018; 249():129-143. PubMed ID: 28238077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]